Abstract
Allogeneic transplantation of pancreatic islets for patients with difficult-to-control diabetes mellitus is severely hampered by the requirement for continuous immunosuppression and its associated morbidity. We report that allogeneic transplantation of genetically engineered (B2M−/−, CIITA−/−, CD47+), primary, hypoimmune, pseudo-islets (p-islets) results in their engraftment into a fully immunocompetent, diabetic non-human primate wherein they provide stable endocrine function and enable insulin independence without inducing any detectable immune response in the absence of immunosuppression. Hypoimmune primary p-islets may provide a curative cell therapy for type 1 diabetes mellitus.
Original language | English (US) |
---|---|
Pages (from-to) | 334-340.e5 |
Journal | Cell Stem Cell |
Volume | 31 |
Issue number | 3 |
DOIs | |
State | Published - Mar 7 2024 |
Externally published | Yes |
Keywords
- hypoimmune
- immune evasive
ASJC Scopus subject areas
- Molecular Medicine
- Genetics
- Cell Biology